Tauopathy Neurons In Psp is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about the cell type. See the content below for detailed information.
Progressive supranuclear palsy (PSP) features characteristic tau pathology in neurons, with 4R tau isoform predominance. These neurons develop distinctive inclusions and undergo degeneration leading to the characteristic clinical syndrome.
- 4R tau: Predominant (tau with 4 microtubule-binding repeats)
- 3R tau: Reduced or absent
- 0N/1N/2N: All isoforms affected
- 6 isoforms in adult human brain
| Type |
Location |
Composition |
| Neurofibrillary tangles |
Perikarya, dendrites |
Paired helical filaments |
| Tufted astrocytes |
Astrocyte processes |
Straight filaments |
| Coiled bodies |
Oligodendroglia |
4R tau |
| Pretangles |
Cytoplasm |
Early tau change |
- Globus pallidus - External and internal segments
- Subthalamic nucleus - Severe involvement
- Red nucleus - Ocular motor nuclei
- Pons - Basis pontis
- Cerebellar dentate nucleus
- Prefrontal cortex - Executive dysfunction
- Anterior cingulate - Apathy
- Striatum - Movement disorders
- Kinases: GSK-3β, CDK5, MAPK
- Phosphatases: PP2A (reduced)
- Sites: AT8, AT100, PHF-1, MC6
- Template-based spread - Prion-like
- Exosome involvement - Intercellular transfer
- Network connectivity - Vulnerability patterns
- Vertical supranuclear gaze palsy - Key diagnostic feature
- Axial rigidity - Neck extension
- Falls - Early, backward
- Dysarthria - Hypokinetic
- Executive dysfunction - Frontal lobe
- Apathy - Motivational deficit
- Behavioral disinhibition - Frontal type
- Dementia - Late stage
- Parkinsonism: Levodopa (modest benefit)
- Dystonia: Botulinum toxin
- Depression: SSRIs
- Tau aggregation inhibitors - Methylene blue derivatives
- Tau immunotherapy - Antibodies, vaccines
- Kinase inhibitors - GSK-3β, CDK5
- Microtubule stabilizers - Davunetide (failed)
The study of Tauopathy Neurons In Psp has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Litvan I, et al. (1996). Clinical research criteria for PSP. Neurology.
- Williams DR, et al. (2007). Tau pathology in PSP. Brain.
- Boxer AL, et al. (2017). New therapies for PSP. Nature Reviews Neurology.